Lantern Pharma Inc. (LTRN) - Dilution Analysis

10-Q filing | 11.3M shares outstanding

8-K filing: Lantern Pharma Inc. completed a registered direct offering and concurrent private placement of common stock and warrants, resulting in approximately $4.4 million in gross proceeds. ($4.4M proceeds)

10-K filing | 10.9M shares outstanding

10-Q filing | 10.8M shares outstanding

10-Q filing | 10.8M shares outstanding

10-Q filing | 10.8M shares outstanding

10-K filing | 10.8M shares outstanding

10-Q filing | 10.8M shares outstanding

10-Q filing | 10.8M shares outstanding

S-3 filing: Lantern Pharma Inc. filed an S-3 form on 2024-05-24 for a shelf offering of common stock, preferred stock, and debt securities, potentially raising up to $150,000,000.

10-Q filing | 10.7M shares outstanding

10-K filing | 10.8M shares outstanding

8-K filing: Lantern Pharma Inc. entered into Securities Purchase Agreements with Bios Fund I QP, LP and Bios Fund I, LP to purchase 145,348 shares of the Company's common stock at $3.44 per share, totaling $499,997.12. ($0.5M proceeds)

10-Q filing | 10.9M shares outstanding

10-Q filing | 10.9M shares outstanding

10-Q filing | 10.9M shares outstanding

10-K filing | 10.9M shares outstanding

10-Q filing | 10.8M shares outstanding

10-Q filing | 10.8M shares outstanding

10-Q filing | 10.9M shares outstanding

10-K filing | 10.8M shares outstanding

10-Q filing | 11.2M shares outstanding

10-Q filing | 11.2M shares outstanding

S-3 filing: Lantern Pharma Inc. is filing an S-3 to offer various securities, including common stock, preferred stock, and debt securities, for up to $200,000,000 in aggregate offering price.

10-Q filing | 11.2M shares outstanding

10-K filing | 11.2M shares outstanding

S-1 filing: Lantern Pharma Inc. is offering 2,613,695 shares of its common stock on a firm commitment basis. The underwriters have an option to purchase up to 392,054 additional shares of common stock to cover over-allotments.

10-Q filing | 6.2M shares outstanding

10-Q filing | 2.0M shares outstanding

8-K filing: A 1.74-for-1 forward stock split became effective on June 11, 2020, and Series A preferred stock was converted into 2,438,851 shares of common stock effective June 15, 2020. Options to purchase 306,743 shares of common stock were granted to directors, officers, or employees at an exercise price of $15.00 per share.

S-1/A filing: Lantern Pharma Inc. registers the offering of up to 1,797,450 shares of the Company's common stock, including up to 234,450 shares upon exercise of the underwriters' over-allotment option.

S-1/A filing: This is a firm commitment initial public offering of common stock of Lantern Pharma Inc. offering 1,563,000 shares with an over-allotment option of 234,450 additional shares.

S-1/A filing: This is a firm commitment initial public offering of common stock of Lantern Pharma Inc.

S-1 filing: This S-1 filing outlines a proposed underwritten public offering of common stock, with a goal of raising at least $25 million, managed by ThinkEquity and Dougherty & Company LLC.